Skip to content

Study · Animal study (in vivo) · dog and rat · 2004

13 results

Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.

Doi N, Hirotani C, Ukai K, Shimada O, Okuno T, Kurasaki S, Kiyofuji T, Ikegami R, Futamata M, Nakagawa T, Ase K, Chihara K

Arzneimittel-Forschung1 Jan 2004Cited by 7 (Europe PMC)

PMID15646370 (opens in a new tab)DOI10.1055/s-0031-1297041 (opens in a new tab)PepBankPUB-15646370
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In conscious rats, the GH-releasing activity of KP-102 was more potent than that of exogenously injected GHRH.

    In plain wordsIn conscious rats, KP-102 released more growth hormone than GHRH did.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH-releasing activity versus GHRH in conscious rats
    Study

    ratn: not reported in source

    conscious rats
    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In conscious rats, the GH-releasing activity of KP-102 was more potent than that of exogenously injected GH-releasing hormone (GHRH).
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In rats under pentobarbital anesthesia, KP-102 and GHRH showed almost equivalent GH-releasing potency.

    In plain wordsIn anesthetized rats, KP-102 and GHRH released about the same amount of growth hormone.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH-releasing potency versus GHRH under anesthesia
    Study

    ratn: not reported in source

    pentobarbital-anesthetized rats
    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Under pentobarbital anesthesia in which endogenous somatostatin secretion is known to be decreased, KP-102 and GHRH, both showed an almost equivalent GH-releasing potency, which was also similar to that of KP-102 in conscious rats.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In conscious dogs, KP-102 showed GH-releasing activity, while GHRH failed to increase serum GH.

    In plain wordsIn conscious dogs, KP-102 raised growth hormone, but GHRH did not.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH release in conscious dogs
    Study

    dogn: not reported in source

    conscious dogs
    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Besides, KP-102 showed GH-releasing activity in conscious dogs as well, while GHRH failed to increase serum GH levels in conscious dogs.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In hypophysectomized rats, the GH-releasing activity of KP-102 was completely absent.

    In plain wordsIn rats with the pituitary gland removed, KP-102 did not release growth hormone.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH release in hypophysectomized rats
    Study

    ratn: not reported in source

    hypophysectomized rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The GH-releasing activity of KP-102 was completely absent in hypophysectomized rats
  5. 05AnimalAnimal study (in vivo)Activity measurement

    In median eminence-lesioned rats, KP-102 GH-releasing activity was present, although secreted GH amounts were significantly lower than in normal rats.

    In plain wordsIn rats with a damaged median eminence, KP-102 still released growth hormone, but less than in normal rats.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH release in median eminence-lesioned rats
    Study

    ratn: not reported in source

    median eminence-lesioned rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but present in median eminence-lesioned rats in which secreted GH amounts were significantly less than those normal rats
  6. 06AnimalAnimal study (in vivo)Activity measurement

    In conscious rats, KP-102 stimulated the secretion of adrenocorticotrophic hormone (ACTH).

    In plain wordsIn conscious rats, KP-102 raised ACTH, a stress hormone from the pituitary gland.

    Peptide
    GHRP-2
    Outcome
    IncreaseACTH secretion in conscious rats
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In conscious rats, KP-102 stimulated the secretion of both adrenocorticotrophic hormone (ACTH) and corticosterone, but not of prolactin.
  7. 07AnimalAnimal study (in vivo)Activity measurement

    In conscious rats, KP-102 stimulated the secretion of corticosterone.

    In plain wordsIn conscious rats, KP-102 raised corticosterone, a stress hormone.

    Peptide
    GHRP-2
    Outcome
    IncreaseCorticosterone secretion in conscious rats
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In conscious rats, KP-102 stimulated the secretion of both adrenocorticotrophic hormone (ACTH) and corticosterone, but not of prolactin.
  8. 08AnimalAnimal study (in vivo)Activity measurement

    In conscious rats, KP-102 did not stimulate the secretion of prolactin.

    In plain wordsIn conscious rats, KP-102 did not raise prolactin.

    Peptide
    GHRP-2
    Outcome
    No significant changeProlactin secretion in conscious rats
    Study

    ratn: not reported in source

    conscious rats
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In conscious rats, KP-102 stimulated the secretion of both adrenocorticotrophic hormone (ACTH) and corticosterone, but not of prolactin.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In normal and monosodium glutamate-treated rats, three weeks of KP-102 showed a growth-accelerating effect.

    In plain wordsIn normal rats and rats treated with monosodium glutamate, three weeks of KP-102 sped up growth.

    Peptide
    GHRP-2
    Outcome
    IncreaseGrowth after three weeks of KP-102
    Study

    ratn: not reported in source

    normal and monosodium glutamate-treated rats
    Outcome group
    Linear growth · Whole body
    Studied dose
    Dose not stated · 3 weeksAs given in this study (rat).

    Source sentences

    Summary
    Three weeks administration of KP-102 showed growth-accelerating effect, a slight increase of body weight and wet weight of some organs in both normal and monosodium glutamate (MSG)-treated rats.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In normal and monosodium glutamate-treated rats, three weeks of KP-102 slightly increased body weight.

    In plain wordsIn normal rats and rats treated with monosodium glutamate, three weeks of KP-102 slightly raised body weight.

    Peptide
    GHRP-2
    Outcome
    IncreaseBody weight after three weeks of KP-102
    Study

    ratn: not reported in source

    normal and monosodium glutamate-treated rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (rat).

    Source sentences

    Summary
    Three weeks administration of KP-102 showed growth-accelerating effect, a slight increase of body weight and wet weight of some organs in both normal and monosodium glutamate (MSG)-treated rats.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In normal and monosodium glutamate-treated rats, three weeks of KP-102 slightly increased the wet weight of some organs.

    In plain wordsIn normal rats and rats treated with monosodium glutamate, three weeks of KP-102 slightly raised the weight of some organs.

    Peptide
    GHRP-2
    Outcome
    IncreaseOrgan wet weight after three weeks of KP-102
    Study

    ratn: not reported in source

    normal and monosodium glutamate-treated rats
    Outcome group
    Linear growth · Whole body
    Studied dose
    Dose not stated · 3 weeksAs given in this study (rat).

    Source sentences

    Summary
    Three weeks administration of KP-102 showed growth-accelerating effect, a slight increase of body weight and wet weight of some organs in both normal and monosodium glutamate (MSG)-treated rats.
  12. 12LabIn vitro (cells)Activity measurement

    In cultured rat anterior pituitary cells, KP-102 directly stimulated GH secretion.

    In plain wordsIn lab-grown rat pituitary cells, KP-102 directly increased growth hormone release.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretion from cultured pituitary cells
    Study

    ratn: not reported in source

    cultured rat anterior pituitary cells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-102 directly stimulated GH secretion from cultured rat anterior pituitary cells
  13. 13LabIn vitro (cells)Activity measurement

    In cultured rat anterior pituitary cells, the GH-releasing potency of KP-102 was significantly weaker than that of GHRH.

    In plain wordsIn lab-grown rat pituitary cells, KP-102 was weaker than GHRH at releasing growth hormone.

    Peptide
    GHRP-2
    Outcome
    DecreaseGH-releasing potency versus GHRH in pituitary cells
    Study

    ratn: not reported in source

    cultured rat anterior pituitary cells
    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    although the GH-releasing potency of KP-102 was significantly weaker than that of GHRH in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.